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 Genital human papillomavirus (HPV) is the most common sexually transmitted infection 
(STI) in the US, with an estimated incidence rate of 6.2 million new cases each year. Men have 
higher instances of certain HPV related outcomes (e.g., head/neck cancers) when compared to 
women, so male vaccination with the HPV vaccine is also paramount to preventing cancer. The 
present study examined the theory of planned behavior (TPB) as a model for predicting HPV 
vaccination intentions among men. Results suggest the TPB was a well-fitting model to the data, 
but not all aspects of the TPB model were predictive of HPV vaccination intentions. Behavioral 
beliefs (e.g.., the belief that vaccination will provide a beneficial outcome) were the only 
significant predictor of HPV vaccination intention in the next 6 months. Perceived norms, 
motivations to comply with norms, attitudes towards the HPV vaccine, and self-efficacy were 
not significant predictors of HPV vaccination intentions. 
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Bridging the gap: Using the theory of planned behavior to predict HPV vaccination intentions in 
men 
 
 
Genital human papillomavirus (HPV) is the most common sexually transmitted infection 
(STI; CDC, 2011a), with an incidence rate of approximately 6.2 million new cases each year in 
the United States (Weinstock et al., 2004). HPV is part of the papillomaviridae family of viruses, 
which affect all parts of the body. For instance, HPV type 1 affects the soles of the feet 
primarily. Over 100 strains of HPV have been identified, with around 40 causing warts (Koutsky 
& Kiviat, 1999). In general, HPV is a virus that replicates deep within the epidermis, creating 
small tumors called “papillomas”. Certain strains are more of a public health concern than others, 
as HPV strains 6 and 11 cause 90% of genital warts, while strains 16 and 18 can cause cervical, 
anal, penile, oropharyngeal, and head/neck cancers (Markowitz et al., 2009; CDC, 2011b; Pisani 
et al., 1997; Koutsky, 1997; Kreimer et al., 2005). HPV does not cause immediate symptoms 
(CDC, 2011a), and as such can go unnoticed until more serious symptoms (genital warts and/or 
cancer) become apparent (CDC, 2011a).   
High-risk strains of HPV can be transmitted sexually, and condoms may not be very 
effective in preventing HPV infection (Schiffman & Kjaer, 2003). HPV can be transmitted 
through vaginal, anal and oral sex, as well as genital to genital contact (CDC, 2009). High-risk 
strains (e.g., HPV strains 16 and 18) are found in 99% of cervical cancers (Bosch & de Sanjose, 
2003). Genital HPV infection may cause other forms of cancers, as it has been linked with breast 
cancer (Antonsson et al., 2011) and lung cancer (Li et al., 2011). It is estimated that at least 50% 
of sexually active individuals have contracted one or more strains of HPV at some point in their 
lives (CDC, 2011b).   
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HPV is estimated to account for about 5% of all cancers world-wide (Parkin, 2006). The 
National Cancer Institute (NCI) estimates that 12,170 new cases of cervical cancer arise each 
year, with around 4,220 associated deaths (NCI, 2012a). There are an estimated 5,820 new cases 
of anal cancer each year, with an estimated death rate of 770 persons per year (NCI, 2011a). 
Penile cancer has an incidence rate of 1,570 new cases each year, and a death rate of 310 persons 
per year (NCI, 2012b). Finally, oropharangeal cancers (laryngeal and pharyngeal) have a larger 
public health impact, with incidence rates estimated at 26,320 new cases yearly and an estimated 
death rate of 5,990 individuals yearly (NCI, 2011b). These cancers have all been related to HPV 
infection from strains 16 and 18, which underscore the importance of HPV prevention through 
vaccination.  
There is no approved test for HPV status in the United States for either men or women 
(CDC, 2011b). This does not mean that HPV cannot be detected, it only illustrates that the CDC 
and FDA have not come to a conclusion on an appropriate test for overall HPV infection. 
Women’s health checks routinely require a Babeș-Papanicolaou (pap) test, by which a trained 
professional inspects the cervix and takes a sample of the cells inside the cervix 
(Womenshealth.gov, 2009). Pap tests in women simply screen for abnormal cells on the cervix 
(Womenshealth.gov, 2009), which are primarily caused by HPV (CDC, 2011b). This provides an 
indirect test for HPV, but cannot causally attribute any abnormal cells to HPV infection. Pap 
tests may also not detect HPV infection, as pap tests tend to sample from the top layer of the 
cervix, and might not detect lower viral load infections in the basal layer of the skin (Trotteir et 
al., 2010). For men, there is not a comparable indirect test for HPV infection. There are generally 
two methods employed by biological studies that assess HPV infection: seroprevalence through 
antibody detection (Dunne et al., 2006), and Polymerase Chain Reaction (PCR) tests to detect the 
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presence of the HPV virus itself (Dunne et al., 2006). These studies provide important 
information about factors associated with HPV infection. 
Seroprevalence studies show that women tend to have higher antibodies for HPV strains 
6, 11, 16, and 18 when tested for HPV (Carter et al., 2001; Eisemann et al., 1996; Slavinsky et 
al., 2001; Strickler et al., 1999; Svare et al., 1997; Stone et al., 2002; Thompson et al., 2004; 
Kreimer et al., 2004). While not as high as their female counterparts, men also have relatively 
high rates of HPV. A review by Dunne and colleagues (2006) illustrated that HPV prevalence in 
men ranges from 20% to as high as 72.9% while the range for women is 14% to 90%. These 
studies illustrate how highly variable HPV infection is, and this can be attributed to HPV not 
being a permanent affliction. This variability could potentially be due to the variability in testing 
for men and women, as well as the inefficiency of those testing methods (Trottier et al., 2010). 
As HPV is an area specific infection much like the herpes-simplex virus, it is often overlooked 
that men need multiple area sampling (e.g., the glans of the penis, the anus, the mouth, the 
central sulcus) to detect actual HPV infection. Many cross-sectional studies that assess HPV 
infection test men from one infection site (e.g., the glans of the penis), which can severely 
underestimate prevalence rates among men (Giuliano et al., 2007). 
HPV infections may clear from the body within a few years for those with healthy 
immune systems (CDC, 2011a). Similar to common influenza and sinus infections, HPV may 
eventually go away without treatment (CDC, 2011b). This assertion is not without contention. 
HPV is still a relatively “new” virus in the research literature, and testing for HPV is still 
inefficient (Trottier et al., 2010). Even with the highly sensitive PCR testing available, it has 
been suggested that HPV may also be a latent virus (Trottier et al., 2010). A latent virus lies 
dormant within a cell and can begin reproducing at any time, typically when the immune system 
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is weakened. Trottier and colleagues (2010) warn that HPV viral load may fall below that which 
is detectable by seroprevalence tests. This may make it appear that HPV is cleared from the 
body, while it may just be that the virus has gone dormant and, therefore, undetectable. Research 
supports the former hypothesis that HPV can be cleared completely from the body. Trottier and 
colleagues (2010) followed women over time, testing for HPV infection and measuring sexual 
behavior. Results of this study showed that women can be re-infected by the same strain of HPV 
over time, and the chief proximal factor to the infection was having a new sexual partner, and 
potentially being re-exposed to HPV. Furthermore, the viral loads for re-infection with the same 
HPV strains were similar at both time points, suggesting that natural immunity after initial 
infection did not diminish the viral burden in succeeding infections later in life (Trottier et al., 
2010). If the latent virus hypothesis were true, it would be unlikely that a new sexual partner 
would potentially “re-activate” the virus, and viral loads for reactivation should not be similar to 
initial infection viral loads. As stated earlier, immune changes would be a more plausible trigger 
for reactivation if HPV were a latent virus. 
 This potentially runs contrary to how the immune system is seen to work. Cell-mediated 
immunity should produce memory cells that will respond to the same strain of a pathogen if the 
body becomes re-infected. This long held belief might not be entirely correct; the immune 
system may react differently to chronic vs. acute viral infections. Wheery and colleagues (2004) 
showed that immune T cells that respond to chronic viral infections do not gain the same 
memory capabilities as do T cells that respond to acute viral infections. Wherry and colleagues 
(2004) suggest that “prolonged exposure to antigen without any rest results in cells that are 
“addicted “ to antigen and cannot persist without it” (p.16008). Antigen independent cells do not 
develop as a result of infection, which creates poor recall of responsiveness, no homeostatic 
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proliferation, and poor antigen-independent persistence when one is re-infected. This can explain 
why people lose immunity to chronic viruses, and potentially explains why HPV can be re-
acquired multiple times. The Gardasil vaccine produces antigen independent memory cells, and 
therefore potentially provides lifetime immunity against HPV strains 6, 11, 16, and 18 once the 3 
shot Gardasil series is completed. 
HPV can be transmitted in many ways that are not isolated to transmission through blood 
contact, and condoms only offer partial protection for the sexual transmission of HPV 
(Schiffman & Kjaer, 2003). Even if a condom is worn, HPV can infect areas around the penis 
that are not covered by a condom (CDC, 2011a). HPV can survive outside the body for a period 
of days and maintain high infectivity (Roden et al., 1997), leaving the potential risk for infection 
from non-sexual contact. In fact, oral HPV transmission may be quite common because of this. 
Prevention of HPV is essential considering the contagiousness of the virus. The cancer risk from 
HPV is likely due to consistent re-infection of high-risk strains (e.g., strains 16 or 18; Bendik et 
al., 2011; Marek et al., 2011). What potentially occurs over the course of an individual’s lifetime 
is that they comes in contact with the same, or different, high-risk strains of HPV and potentially 
develop HPV-related cancers as an outcome. 
As the cancer risk associated with HPV infection is clear, the FDA approved a 
quadrivalent vaccine (Gardasil) produced by Merck & co., Inc. to provide immunological 
protection from HPV strains 6, 11, 16 and 18 in persons 9 through 26 years old on June 8, 2006 
(FDA, 2010; FDA, 2006). Cervarix is an additional vaccine that has been approved to prevent 
HPV. Cervarix protects against two cancer-causing strains of HPV (strains 16 and 18). This 
vaccine is only marketed for girls between the ages of 9 to 25 (FDA, 2011). 
HPV Vaccine Efficacy. 
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Vaccines are an excellent strategy for reducing, and potentially eradicating, infectious 
diseases (Andre et al., 2008). On October 21, 2009, the Advisory Committee on Immunization 
Practices (ACIP) provided a passive recommendation for males between the ages of 9 and 26 to 
be vaccinated with the quadrivalent HPV vaccine Gardasil, but suggested that the vaccine not be 
part of routine vaccinations for men (CDC, 2010b).  The intent of male vaccination, according to 
the CDC, is to prevent genital warts and subsequent female infection (CDC, 2010b). The 
Gardasil vaccine is taken in a 3 shot series, after the initial dose, the vaccinated individual is 
asked to return 2 months later for a second dose, and again for a third dose 6 months from the 
initial first dose date (Merck, 2011). Vaccination with Gardasil should start early, before an 
individual sexually contracts HPV (CDC, 2011b). While ideal to be vaccinated younger, the 
vaccine is still suggested for individuals up to ages 26 (CDC, 2011b). As stated earlier, the virus 
is cleared in about 2 years in healthy adults (CDC, 2011b). Owing to this, it is still considered to 
be effective to become vaccinated with Gardasil after sexual intercourse has been initiated (CDC, 
2011b). The Gardasil vaccine has been shown to be effective in men, and it can reduce more than 
90% of genital warts, as well as greater than 90% of persistent complications, including cancers, 
that are caused by HPV types 6, 11, 16, and 18 (Giuliano & Palefsky, 2008). 
Gardasil has been shown to be an effective vaccine for prevention of HPV viruses 6, 11, 
16, and 18 (Giuliano, Palefsky, & Goldstone et al., 2011). Studies have illustrated the overall 
effectiveness of Gardasil as well as its effectiveness in men (Giuliano, Palefsky, & Goldstone et 
al., 2011). Long-term effectiveness is currently unknown, but research suggests lifetime 
immunity as a result of full vaccination with Gardasil (CDC, 2011d). 
 Harm rates associated with Gardasil are relatively low. Harm rates are defined as any 
harmful event that occurs after a Gardasil vaccine is administered. There are two general 
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classifications of harm, those that are non-serious (e.g., headache, nausea, fainting after 
injection) and those that are serious (e.g., death, permanent disability, life-threatening illness). 
These reports are tracked through the Vaccine Adverse Effects Reporting System (VAERS) and 
reviewed by both the FDA and the CDC. These reports are not limited to complications 
immediately following vaccination, but encompass any negative consequence perceived by the 
individual to be causally attributed to the vaccine administered at any time after the vaccine was 
received. From 2006 to December 2008, 23 million individuals were vaccinated with Gardasil 
(CDC, 2011c). Of those 23 million, 12,424 individuals reported side effects to VAERS, of which 
94% were considered non-serious (CDC, 2011c). The remaining 772 cases (6% of total reports) 
consisted of serious side effects, including 32 deaths (CDC, 2011c). The deaths reported to 
VAERS were all explained by factors unrelated to vaccination, suggesting that they were not 
causally related to receiving the Gardasil vaccination (CDC, 2011c); this further illustrates the 
safety of the Gardasil vaccine.   
Cost effectiveness analyses are often employed to justify the use of vaccinations. The 
simple paradigm of cost-effectiveness is that if a sufficient amount of cost is expended to prevent 
enough individuals from acquiring a disease, and the cost of the expenditure is greater than the 
cost of treatment of that disease, then that expenditure is considered cost effective. As applied to 
HPV vaccination, does it simply cost less to vaccinate a group of people than it is to pay for 
treatment? The CDC has, for now, decided that it is only cost effective to strongly suggest 
vaccinations of women against HPV (CDC, 2010c). The goal of solely vaccinating women is that 
if women are vaccinated, then HPV related cancers will largely be prevented, and this will also 
protect heterosexual men from infection.  
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However, for the most part, vaccinating men has also been consistently shown to be cost 
effective (Elbasha & Dasbach, 2010; Chesson et al., 2011; Kreimer & Chaturvedi, 2011). While 
most literature strongly supports HPV vaccination in men (e.g., Elbasha & Dasbach, 2010, 
Kreimer & Chaturvedi, 2011), Chesson and associates (2011) suggest that vaccination of men 
may not be cost effective if vaccine uptake among women is above 80%. There are two problems 
with this assertion. Firstly, it ignores the social aspect of HPV vaccination and the hesitation of 
some mothers to vaccinate their child with a vaccine that prevents an STI (Gordon et al., 2011), 
which may reduce vaccine uptake in the population of women. Giuliano & Salmon (2008) argue 
that vaccination of men with Gardasil will become inevitable, as the current program of 
mandated vaccines for one gender fails to adequately control the spread of HPV due to less than 
desirable amounts of uptake among girls and women in the population. There are no current 
population estimates that illustrate the actual uptake percentage of the HPV vaccine by women, 
but a review of the literature on HPV vaccine uptake among women revealed a low estimate of 
37%; Bartlett et al., 2011). This estimate is much lower than the suggested 80% uptake among 
women to make male vaccination not cost effective (Chesson et al., 2011). This approach also 
ignores the sexual experiences of men who have sex with men (MSM; Gilbert et al., 2011b), as 
they are left completely unprotected in a theoretical situation whereby all women are potentially 
vaccinated.  
Lessons Learned From Gendered Vaccination Programs 
The NCI predicts that there will be 12,170 new cases of cervical cancer in 2012, with 
4,220 associated deaths (NCI, 2012c). Cervical cancer is almost always caused by HPV (NCI, 
2012c), but it is not the only cancer that is highly associated with HPV. Almost all anal cancers 
are caused by HPV, and a large portion of oropharyngeal and penile cancers are causally related 
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to HPV infection (Parkin & Bray, 2006; Watson et al., 2008); these cancers, however, can infect 
both sexes. 
Vaccination programs that have targeted only one gender have generally failed. Out of 75 
countries who used the rubella vaccine in 1996, 9% of those countries selectively immunized 
women (Robertson et al., 1997). In the United Kingdom, the rubella vaccine was solely given to 
young girls, caregivers, and at-risk older women. The weakness of this approach became evident 
in 1996 when the rubella virus resurged as a result of susceptibility among men (Tookey et al., 
1999; Vyse et al., 2002). It is therefore argued that any viral eradication effort must include both 
genders. Vaccinating men has the independent benefit of protecting men from HPV related 
cancers, but can also aid in the prevention of cervical cancer in women. The rubella virus is 
fundamentally different from HPV in that it is not sexually transmitted, and not typically serious. 
However, considering how contagious HPV is, a similar pattern of resurgence is potentially 
possible. 
HPV and Men. 
Why Study HPV in Men? 
Whereas women have a higher incidence of some HPV related cancers than men, the 
vaccine is passively suggested to be given to males ages 9 through 26 to prevent genital warts 
(CDC, 2010b; CDC 2011b). Every year in the United States, there are an average of 400 men 
who are diagnosed with HPV-related penile cancer, 1,500 men are diagnosed with HPV-related 
anal cancer, and 5,600 men each year are diagnosed with oropharyngeal cancers (CDC, 2011a). 
While the penile cancer rate is low and rare, it has a very high mortality rate associated with 
infection (Giuliano et al., 2010). Almost half of all penile cancers are estimated to be due to HPV 
infection (Parkin & Bray, 2006), and men have higher incidences of every type of oral HPV-
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related cancer than do women (CDC, 2011a). Oropharyngeal cancer incidences have decreased 
slightly over time, with a stronger decrease for women than for men (NCI, 2011c). Even with 
overall oropharyngeal cancer rates decreasing, men still have higher overall incidences of 
oropharyngeal cancers than women (NCI, 2011c). Further, men have a higher mortality rate 
associated with oropharyngeal cancers than do women (NCI, 2011c). This further illustrates that 
women are not the sole risk group for cancerous HPV related outcomes. 
 Anal cancer trends continue to increase for men and women, with men having shown 
greater increases in anal cancer morbidity than women over time (NCI, 2011b). Anal cancers 
among men in the US have gone from 0.5 per 100,000 in 1974 to 1.4 per 100,000 in 2008 (NCI, 
2011b). There have been statistically significant trend increases in anal cancers over time for 
both men and women over the past 33 years, but these incidences of anal cancer among men are 
greater than those among women (NCI, 2011b). Considering the high mortality rate associated 
with penile cancer, the increases in male anal cancer, and the large gender differences in 
oropharyngeal cancer rates, prevention efforts need to be aimed at men as well as women. 
Genital Warts 
Cancer is not the only risk associated with HPV. While strains 16 and 18 are causally 
related to cancer, strains 6 and 11 are causally attributed to genital warts (CDC, 2011a). Genital 
warts in themselves can cause negative outcomes. For instance, a study by Smith and colleagues 
(2010) illustrated that men with HPV in Kenya were almost twice as likely to later contract HIV.  
The authors suggest that genital warts may be a potential reason for this, as the inflammation 
caused by genital warts may weaken the natural skin barrier and increase likelihood of HIV 
transmission (Smith et al., 2010). 
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Genital warts tend to occur approximately 3 to 6 months after initial infection, but can 
stay dormant in the host for years before any manifestations of warts occur (Persson et al., 1993; 
Clarke et al., 1996; Sheppard et al., 1995). For those who do develop genital warts, 
reoccurrences of warts are common (Sheppard et al., 1995; Filiberti et al., 1993; Maw et al., 
1998; Voog et al., 1992) and treatment of warts with harsh chemicals and acids can be painful, 
debilitating, and expensive. 
There are severe mental health implications for contracting genital warts, in addition to 
the earlier stated physical health risks. Patients with genital warts report greater psychological 
distress, including anger, shame, isolation, depression, and guilt (Jeynes et al., 2009). Those with 
genital wart symptoms report a lower Health Related Quality of Life (HRQoL) than those 
without warts (Jeynes et al., 2009). Internalized shame and intrusive thoughts associated with 
genital wart infection are strong predictors of poor HRQoL (Jeynes et al., 2009). Moreover, 
shame associated with having an STI is associated with not seeking medical treatment among 
adolescents (Fortenberry, 1997). As a result of not seeking medical treatment, young adolescents 
may expose themselves to greater risks (e.g., contracting HIV or other STIs). There are 
potentially severe health consequences for men who contract genital warts from HPV infection, 
and the mental health consequences of having genital warts cannot be ignored.  
Associated Risk Factors for HPV Infection in Men 
There are differences between men who have sex with women (MSW) and MSM in 
terms of HPV infection and cancer related outcomes (Johnson et al., 2004; Gilbert et al., 2011c; 
Anderson et al., 2008; Pierangeli et al., 2008). MSM tend to have generally more positive 
attitudes towards vaccinating against HPV with the Gardasil vaccine (Gilbert et al., 2011b). This 
may be due to MSM being consistently at risk for STIs, and the Gardasil vaccine among MSM 
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individuals tends to be evaluated more favorably in MSM than in MSW (Gilbert et al., 2011b). 
Moreover, having anal sex with other men also predicts HPV infection (Lajous et al., 2005). 
HPV is a virus that does not just exist internally, as studies have shown that the scrotum 
and inguinal area can harbor large amounts of HPV (Dunne, Nielson, Stone, et al., 2006). This 
adds to infection risk, as the virus can easily move to more habitable areas (e.g., the coronal 
sulcus of the penis, or the anus). Circumcision is a protective factor in preventing later HPV 
infection, as the virus can stay housed within the foreskin of the penis longer than those in 
circumcised men, creating a longer persistence of the virus (Svare et al., 2002). HPV can survive 
for long periods of time in the glans of the penis underneath the foreskin. Biological studies have 
illustrated that men who are not circumcised are more likely to be infected with HPV than those 
who are circumcised (Svare et al., 2002).  
 HPV type 16 is among the most aggressive and virulent strain in terms of cancer risk, and 
past research has shown it to be most common in men (Dunne, Nielson, Stone, et al., 2006). In a 
study by Lajous and colleagues (2005), 51.1% of men with HPV had more than one strain. This 
suggests that men may be at a higher risk for certain HPV related cancerous outcomes, as 
multiple HPV infections are associated with greater persistence of the virus (Kjaer et al., 2005; 
Lajous et al., 2005).  
HPV Attitudes, Willingness to Vaccinate, and Intentions to Vaccinate.  
Evidence has shown that having a vaccine available does not necessarily lead to high 
uptake in the population (Gonik, 2006; Zimet et al., 2000). Attitudes towards vaccination are a 
likely reason for this, particularly as Gardasil has attracted a lot of attention on the Internet as a 
potentially dangerous vaccine. Some barriers to receiving the Gardasil vaccine in men include 
  
  
  
   
13 
the belief that men do not benefit from the Gardasil vaccine (Ferris et al., 2008) and that Gardasil 
is too new to be trusted (Crosby et al., 2011).  
Another challenge associated with encouraging HPV vaccination is that HPV infection is, 
for the most part, invisible. HPV does cause genital warts, which are a very visible 
manifestation, but this manifestation can easily be suppressed by the immune system, similar to a 
herpes virus. Long-term outcomes of HPV include cancer, but unlike some other STIs, there are 
very few immediate outcomes of HPV infection; even genital warts take as long as 6 months to 
surface, and only occur in a small proportion of those infected with HPV (National Library of 
Medicine, 2011; CDC, 2011a). As viral symptoms from HPV are essentially invisible for some 
time, this could cause individuals who are infected to not attend to their infection. Research has 
shown general support for this, as a lack of knowledge of, and familiarity with HPV predicts a 
lower likelihood of vaccination (Bendik et al., 2011). 
Sexual orientation. Research on MSM’s attitudes towards the HPV vaccine has shown 
gay men to be more favorable to the Gardasil vaccine than are heterosexual men (Gilbert et al., 
2011b). Among MSM, those who are HIV positive are more favorable towards the Gardasil 
vaccine, potentially because they are more health conscious, as HIV treatment adherence is 
paramount for those infected (Gilbert et al., 2011b). Gay and bisexual identified men tend to 
have more accurate knowledge of HPV related outcomes, as well as higher perceived likelihood 
of contracting HPV (Gilbert et al., 2011b). MSM tend to have more severe HPV related 
outcomes than do heterosexual men (Gilbert et al., 2011b), and are 17 times more likely to 
develop anal cancer from HPV 16/18 infection than do MSW (CDC, 2011b).  
While the differences between straight and gay men in terms of outcomes have been 
demonstrated, HPV type 16 is among the most common HPV strain among both gay and 
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heterosexual identified men (Nyitray, Carvalho da Silva et al., 2011). As HPV type 16 is the 
most virulent cancer causing strain of HPV (Svare et al., 2002), it is important for prevention 
work to address both gay and heterosexual identified men.  
Cost. The findings are mixed as to how the cost of Gardasil is associated with intentions 
to receive the Gardasil vaccine. While on one hand, cost is a factor that is consistently predictive 
of willingness to vaccinate, acceptance of the HPV vaccine, and intentions to receive the vaccine 
among men, gay men, and women (Simatherai et al., 2009; Allen et al., 2009; Gerend & Barley, 
2009; Daley, Marhefka, Buhi et al., 2010; Burke, Vail-Smitch, et al., 2010; Young et al., 2010; 
Rhodes & Arceo, 2004). On the other hand, cost may not be as consistent a barrier as it has been 
reported in past research. In multivariate analyses, concerns about HPV vaccine cost seems to 
disappear as a significant predictor of HPV intentions to vaccinate, and acceptability of the 
vaccine (Hernandez et al., 2010; Crosby et al., 2011). This suggests that cost may be concomitant 
with other predictors (e.g., having healthcare), and may not be an independent predictor of 
receiving the vaccine when added to a multivariate analysis. In a study by Hernandez and 
colleagues (2010), those who cited cost as a barrier to vaccination were more likely to intend to 
vaccinate with Gardasil, and those who indicated that cost would be a major deciding factor in 
HPV vaccination were more likely to intend to vaccinate as well. This could be due to the many 
different cross-sectional samples utilized to study the effects of cost on HPV vaccine acceptance, 
willingness, and intentions to vaccinate.  
The retail cost of the HPV vaccine is $130 dollars per dose, for a total of $390 dollars for 
the entire 3 shot series (CDC, 2011d). This cost is much higher than that of other vaccines, and 
this potentially creates a greater barrier to vaccination for those without means to pay. 
Considering this, men’s estimation of the personal amount they are willing to pay for the 
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Gardasil vaccine is, on average, between $110 and $130. This could further illustrate that cost 
may not be as great a barrier as it is reported to be. What is studied less is the perceived ability to 
obtain the vaccination, which may be also be associated with perceived ability to pay.  
The media. Straight identified men report a lower acceptance of the HPV vaccine than 
do women (Gilbert et al., 2011). When compared to MSM, straight men have less positive 
attitudes towards HPV vaccination. Another study showed that that having greater knowledge of 
HPV and having heard of the vaccine was associated with a decreased willingness to receive the 
vaccine (Daley et al., 2010). A potential reason for this is a lack of knowledge about HPV and 
the Gardasil vaccine. The outreach programs by Merck & co. have urged women to be 
vaccinated in their advertisements. The media may have a strong influence on health beliefs and 
behaviors (Hay et al., 2009), and these advertisements may have influenced men to not see 
themselves at risk. In fact, research on male HPV vaccine attitudes has shown this to be a 
common belief. Men have reported in qualitative studies that they are not worried about HPV 
(Allen et al., 2009), do not perceive themselves as at-risk for HPV infection (Allen et al., 2009), 
and believe that the HPV vaccine does not benefit men (Crosby et al., 2011). Some research 
shows that media can be used to improve male intentions to receive the Gardasil vaccine. For 
example, a study by DiClemente and colleagues (2011) concluded that any form of HPV 
prevention message given via a short PowerPoint presentation was enough to significantly 
increase intentions to vaccinate with Gardasil among men.  
 There is a wealth of misinformation about vaccines on the Internet (Kata, 2010; 
Zimmerman et al., 2005), including entire websites dedicated to “proving” that Gardasil causes 
seizures, disability, and death in many of those who receive the vaccine (e.g., 
“TruthAboutGardasil.com”). These websites tend to use anecdotal evidence, logical fallacies, 
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and scare tactics to suggest that Gardasil is not safe (Zimmerman et al., 2005). In spite of the low 
harm rates associated with receiving the Gardasil vaccine, there is still mistrust of the Gardasil 
vaccine and vaccinations in general on the Internet. The Internet represents a pathway for 
individuals to gain information that may or may not be accurate, and vaccine information 
gathered from the Internet may contain false information (Zimmerman et al., 2005). What is 
most concerning about these claims is that they are typically untrue, as Gardasil is as safe as 
other vaccines available (FDA, 2009). This information may in turn steer men away from 
thinking they are at risk for HPV infection, that HPV is dangerous, and that men do not need to 
be protected from HPV. 
Moreover, television commercials by Merck & co. are targeted at educating women about 
HPV infection, and encouraging early vaccination with Gardasil. These advertisements are 
deliberately targeted at women. Some newer advertisements have begun to target men and boys, 
but these advertisements may not be widespread enough to have the intended impact. Despite 
CDC suggestions that men vaccinate against HPV along with women, there are few 
advertisements targeted at a male audience. This may create a normative belief, suggesting to 
men that they do not need the Gardasil vaccine, and potentially engender a belief that HPV is not 
a concern for them. Despite clear research on the topic of media influence, there is very little 
literature that seeks to identify how media influences both Gardasil vaccine attitudes, and 
intentions to receive the Gardasil vaccine. 
The media can also present images and discourse from political figures that may relate 
inaccurate information on vaccination. For instance, on September 12, 2011 Republican 
presidential hopeful Michele Bachmann publically proclaimed that Gardasil causes retardation, 
based off an encounter with a mother who claimed that Gardasil caused her daughter to become 
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mentally retarded. This comment sparked outrage from the American Academy of Pediatrics 
(AAP), who insisted that the vaccine was safe (AAP, 2011). Statements like this from political 
figures or media personalities may make individuals, including men, question the safety of the 
Gardasil vaccine unnecessarily as they come into contact with inaccurate media sources. 
Sexual behavior. As sexual behavior is the primary method by which individuals 
contract HPV, past research has assessed how sexual activity influences attitudes towards the 
HPV vaccine. Research generally shows positive relationships between sexual behavior and 
HPV vaccine acceptance, willingness, and intentions to vaccinate. Being sexually active, having 
multiple partners, and having oral sex are all associated with willingness to vaccinate with the 
HPV vaccine, acceptance of the Gardasil vaccine (Gerend & Barley, 2009; Ferris et al., 2009; 
Crosby et al., 2012). These findings can be explained in many ways. Men who have sex often 
may be more informed about STI prevention, and may have more positive attitudes towards 
Gardasil as a result. Frequent sexual activity may expose an individual to resources whereby 
information about HPV is available. For instance, a sexually active individual may retrieve 
condoms from free resources (e.g., medical clinics) and subsequently gain information about 
Gardasil and HPV from resources available there. 
 One robust predictor of intent to vaccinate among men is ever having had oral-genital sex 
(Crosby et al., 2011; Crosby et al., 2012). This finding is curious, as it seems that oral-genital sex 
is associated with intent to vaccinate, over and above other sexual behavior predictors that might 
seem more relevant (e.g., multiple penile-vaginal sex partners, having had sex with a male 
partner, mutual masturbation, and unprotected penile-vaginal sex). There are a few reasons that 
might explain this relationship. Oral sex tends to be more common than vaginal sex in young 
samples (Halpern-Felsher et al., 2005; Malacad & Gretchen, 2010). More frequent oral sex might 
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also create a heightened awareness about disease transmission, and subsequent perceived risk for 
oral cancers (Crosby et al., 2012). This in turn may lead individuals to be more willing to take 
any medical preventative measures to reduce any kind of infection (e.g., receiving the Gardasil 
vaccine).  
Medical provider influence. In numerous studies, willingness to receive Gardasil was 
associated with a belief that a doctor would recommend the vaccine (Gilbert et al., 2011a; 
Gilbert et al., 2011b; Daley et al., 2010). Medical providers can be a source of knowledge about 
disease and health behaviors. Medical providers are authority figures that can dispel incorrect 
information learned from media sources. In fact, the field of health psychology has examined 
patient-provider interactions in terms of health behaviors (Barlett et al., 1984; Becker, 1985), 
strengthening the notion that medical providers can cause behavior change.  
 Medical attendance can be a gendered event, as women tend to take a more active role in 
their medical decisions (Arora & McHorney, 2000), and women tend to receive more medical 
information than men (Waitzkin, 1985). Women often receive routine pap tests, whereas men 
have no comparable routine examination that could potentially detect HPV related cancers in 
their early stages. Pap tests have a clear HPV-related focus and patients may potentially dialogue 
with their medical provider about the vaccine. Among women, a provider recommendation for 
vaccination is significantly associated with being vaccinated against HPV, with a stronger 
recommendation being more likely to increase vaccination than a weaker recommendation 
(Rosenthal et al., 2011). 
Racial differences. The literature on racial differences in HPV vaccine acceptance, 
willingness, and intentions to vaccinate is mixed. Many studies that have controlled for race have 
found significant effects over and above race. However, studies have also shown significant 
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differences between races in vaccine acceptance and willingness to receive the Gardasil vaccine 
(Ferris et al., 2009). A study by Ferris and colleagues (2009) demonstrated that white men were 
generally more undecided about receiving the HPV vaccine, and when compared to White men, 
Black men were more willing to receive the HPV vaccine. 
 Racial differences in intentions to receive the Gardasil vaccine may attenuate in 
multivariate statistical analyses. Many studies on racial differences illustrates that race may not 
be an influential factor in intentions to receive the Gardasil vaccine. For example, Daley and 
colleagues (2010) found that race was not a significant predictor of intentions to receive the 
Gardasil vaccine, while Hernandez and colleagues (2010) found no racial differences in 
awareness, attitudes, and intent to vaccinate with the HPV vaccine. 
 One potential criticism of these research studies is that they have utilized largely white 
samples. All articles cited had a majority of white identified individuals as participants. 
Furthermore, these studies may be influenced by time of data collection. Variability in any type 
of HPV vaccine related questions could be constricted, as the HPV vaccine has only been 
available since 2006. A lack of racial diversity in the samples may be a crucial variable that may 
mask true racial differences in intentions to receive the HPV vaccine. 
Use of Theoretical Frameworks in HPV Research 
 Past research has attempted to utilize portions of theoretical models to predict Gardasil 
acceptance, willingness, and intentions to initiate Gardasil vaccination. These studies mainly 
look at variables that are a part of the health belief model (HBM), but further provide theoretical 
justification for use of other theory.  
The Health Belief Model 
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 The HBM suggests that the likelihood of an individual participating in an action 
necessary to avoid a disease is dependent on the perceived susceptibility to the disease, the 
perceived severity of the disease, the perceived benefits of engaging in a behavior that will 
prevent a disease, the perceived barriers to engaging in that behavior, and “cues to action” which 
refer to influences, either inside or outside, oneself that encourage one to engage in a behavior 
(e.g., breaking out with acne would be a cue to action to engage in face washing behavior). 
 Past studies have shown some support for parts of the health belief model in predicting 
intentions to vaccinate with HPV vaccine. In a study of parental intentions to vaccinate their 
children, parent’s perceived benefits of vaccination and perceived susceptibility of their child 
contracting HPV were significant predictors of intentions to vaccinate their male child (Dempsey 
et al., 2006). Among adult men, perceived susceptibility to HPV was associated with willingness 
to receive the HPV vaccine, and willingness of parents to vaccinate their child (Crosby et al., 
2011; Dempsey et al., 2006; Dempsey et al., 2011), as well as in other studies that predicted 
feelings towards receiving the HPV vaccine (Boehner et al., 2003; Friedman and Shepeard, 
2006). Specifically in a study by Dempsey and colleagues (2011), all arms of the HBM were 
predictive of parental intent to vaccinate their young, adolescent male children, except for 
perceived severity (cues to action were unmeasured). Perceived barriers such as cost and vaccine 
safety (discussed earlier) may not be the best predictors of Gardasil vaccine acceptability in men. 
In a recent study of women, Gerend & Shepherd (2012) found that perceived severity in itself 
was not a significant predictor of receiving the HPV vaccine. Moreover, perceived severity has 
not been associated with vaccine acceptability in other studies of samples with men and women 
examining an array of vaccination behaviors (Boehner et al., 2003; Dempsey et al., 2006; Kahn, 
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Rosenthal, Hamann, & Bernstein, 2003). A caveat to this research is that these studies examined 
acceptability, and not likelihood, willingness, or intentions to receive the HPV vaccine.  
 Perceived severity of HPV has also been a poor predictor of acceptability of the Gardasil 
vaccine in studies comparing gay and bisexual men against heterosexual men. HIV negative men 
have no relationship between perceived severity and Gardasil acceptability, while HIV positive 
men with higher perceived severity have greater acceptability of the Gardasil vaccine (Gilbert et 
al., 2011a). An interesting factor in male Gardasil acceptance and perhaps intentions to receive 
the vaccine seems to be HIV status. Gilbert and colleagues (2011b) found that HIV infected gay 
men had a strong positive relationship between perceived severity of HPV and intentions to 
vaccinate, while HIV-negative gay men had no relation between perceived severity and 
intentions. This could illustrate that individuals with chronic illness may be more sensitive to 
preventative health measures. 
 The HBM has historically done a poor job of predicting the likelihood of receiving the 
Gardasil vaccine. In many studies, HBM factors like perceived severity of HPV infection were 
not predictive of acceptability of the HPV vaccine (DiAngi, Panozzo, Ramogola-Masire, 
Steenhoff, & Brewer, 2011; Boehner et al., 2003; Dempsey et al., 2006; Kahn et al., 2003). 
Many studies do not use theoretical frameworks to study Gardasil vaccine initiation, and of those 
studies that do, they sample mostly women. Furthermore, the use of the HBM has often been 
studied with parents’ intentions to vaccinate their children. This leaves adults relatively ignored 
in the literature that attempts to use theory as a framework to predict intentions to receive the 
HPV vaccine. Instead of using the HBM as a model for predicting health behavior engagement, 
the Theory of Planned Behavior (TPB) may provide a more accurate framework for predicting 
health behaviors, such as receiving the Gardasil vaccine.  
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The Theory of Planned Behavior 
 The TPB posits that the strongest predictor of any given behavior is the intention to 
engage in that behavior (Ajzen, 1991). The TPB model posits that attitudes towards the behavior, 
perceived normativity of that behavior, and one’s ability to control their engagement in that 
behavior (perceived behavioral control) are the most proximal predictors of intentions (Ajzen, 
1991). Attitudes in the TPB consist of two constructs: behavioral beliefs, and attitudes towards 
the behavior. Behavioral beliefs refer to the perceived consequences of engaging in a particular 
behavior, while attitudes towards the behavioral refer to the evaluation of the behavior as 
positive or negative. A recent comparison of the HBM and the TPB has given strong evidence 
for the TPB as the better model for predicting vaccine uptake among young adult women 
(Gerend & Shepherd, 2012). As such, the TPB may perform best as a model for predicting HPV 
vaccine intentions in men as well. Furthermore, TPB has also been successful in predicting many 
different health behaviors (e.g., Armitage & Conner, 2001; Bogart & Delhanty, 2004).  
Perceived norms. Perceived norms represent the perception of important others’ beliefs 
regarding a behavior (Ajzen, 1991). Moreover, perceived norms also include a reflection on how 
relevant one perceives those beliefs of important others’ to be.  Past research has illustrated some 
of the ways in which norms can influence the willingness to receive the HPV vaccine. For 
example, a study by Reiter and colleagues (2011), young boys were more willing to receive the 
HPV vaccine if they perceived that their peers would accept them for it, if they would later regret 
not getting the vaccine, and perceived themselves to be vulnerable to getting HPV; of these 
predictors, perceived peer acceptance was the strongest. There are more promising predictors of 
willingness to receive the Gardasil vaccine that are associated with parental attitudes. Among 
minor young adults, parental attitudes tend to be strongly associated with male child attitudes 
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towards HPV (Reiter et al., 2011). In fact, recommendations from powerful others (e.g., parents, 
doctors) tend to be strong predictors of acceptance of the Gardasil vaccine (Ferris et al., 2008, 
2009; Boehner et al., 2003; Hollander, 2010). 
Attitudes. Attitudes in the TPB model consist of two constructs: Behavioral beliefs and 
attitudes towards the behavior. Behavioral beliefs refer to the believed consequences for 
engaging in a particular behavior. Attitudes towards the behavior refer to the evaluation of the 
behavior as positive or negative. Together, these two constructs represent the attitudes variable in 
the TPB model. 
 Parental attitudes towards HPV have been correlated with willingness to receive the 
Gardasil vaccine in young male children. A study by Reiter and colleagues (2011) measured the 
predictors of parent intention to vaccinate their male child (ages 11-17) with an HPV vaccine, as 
well as child intention to receive an HPV vaccine. Results showed that numerous different 
attitudes (e.g., harmfulness of the vaccine) towards the HPV vaccine were significant, predictors 
of intentions to vaccinate their child. Uncertainty about the HPV vaccine seems to be readily 
apparent in all research reports that examine it. A qualitative investigation by Allen and 
colleagues (2009) reported that the men in their sample reported apprehension towards Gardasil 
based on reported fears of side effects and safety of the vaccine. One participant even stated that 
“there’s been so many things that women have taken that have supposed to help them which 
have ended up being negative for them” (Allen et al., 2009, p.536). These beliefs that Gardasil is 
unsafe, in turn, have been shown to predict, in general, negative attitudes towards receiving the 
HPV vaccine (Ferris et al., 2009; Boehner et al., 2003). These predictors also tend to be very 
robust. A study by Crosby and colleagues found that believing that the HPV vaccine was too 
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new to receive was one of three remaining significant predictors of intent to vaccinate with 
Gardasil when entered into a multivariate model along with many other variables. 
 The items created by (Reiter et al., 2011) for the purposes of their research contained 
questions that tapped into attitudes towards Gardasil vaccination, but have mainly been used for 
parental attitudes towards vaccinating one’s child (Reiter et al., 2011). These attitudinal factors 
tend to be predictive of receiving the Gardasil vaccine. Past research has taken portions of 
attitudinal beliefs (as defined by the TPB) to predict HPV vaccine acceptance and intention to 
initiate vaccination, but attitudinal variables tend to be poor predictors of a behavior alone 
(Fishbein & Ajzen, 1974). Little research has specifically looked at attitudes towards HPV and 
Gardasil among adult men. 
Perceived behavioral control. Perceived Behavioral Control (PBC) is the most robust 
predictor in the TPB. This construct represents the perceived ease at which an individual believes 
they can engage in a particular behavior. PBC theoretically predicts intentions to engage in a 
behavior, as well as directly predicts the behavior itself (Ajzen, 2002). Much research has used 
measures of self-efficacy to describe PBC, but Ajzen (2002) objects by stating that PBC 
conceptually represents both perceived self-efficacy, and perceived controllability. For efficacy 
to be truly predictive of a behavior, an individual must not only believe he or she can engage that 
behavior (self-efficacy), but also feel that they have control over their ability to engage in that 
behavior (perceived controllability). Furthermore, Terry & O’Leary (1995) illustrated that 
perceived controllability and perceived self-efficacy were two separate parts of PBC, and have 
better predictability separately than together. Ajzen (2002) concludes that PBC is better 
conceived as a factor that makes up two latent constructs: perceived self-efficacy and perceived 
controllability.  
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 No study to date has examined PBC in relation to receiving the Gardasil vaccine, but a 
few studies have included measures that shed light on its predictive power. A study by Crosby 
and colleagues (2011) found that self-efficacy to be vaccinated with Gardasil is not predictive of 
intentions to receive the vaccine. A study by Hernandez and colleagues (2010) included a 
variable in their analysis of vaccination intentions that asked whether transportation to a clinic to 
receive the vaccine would influence vaccination intentions; this was not significant in their final 
analysis. The studies suggest that PBC-related variables may not factor into intentions to receive 
the Gardasil vaccine. 
 While past studies may not support PBC in predicting HPV vaccination, the context of 
the research on Gardasil and the HPV vaccine must be taken into account when critically 
analyzing the results of past research. Gardasil was not approved for male use until years after 
the vaccine was introduced, and the vaccine is still relatively new. Older studies, and even 
currently published ones, use data from around or before the time when Gardasil was approved 
for male use. It is plausible that PBC may not have been a relevant predictor of intentions to 
receive the HPV vaccine because participants may never had heard of it, or they did not believe 
it is for them. In fact, Crosby and colleagues (2011) also found that belief that one should wait to 
be vaccinated because the Gardasil vaccine is too new was a significant predictor of not 
intending to receive the Gardasil vaccine. The key fact that must be considered for future 
research is that the more recent studies, with newer data, will provide the most useful 
information on intentions to receive Gardasil, as the vaccine becomes more normative and the 
risks associated become better understood by the lay population.  
 As many studies use the health belief model as a partial framework, but do not complete 
the model by including all relevant predictors. This is a common criticism of the literature that 
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utilizes the health belief model (Bogart & Delahanty, 2004). Psychosocial theories on health 
behaviors are helpful for predicting whether or not individuals participate in certain health 
behaviors, including receiving the Gardasil vaccine. While these studies present interesting 
associations of willingness to receive the HPV vaccine, the TPB provides a standard framework 
that predicts intentions to engage in health behaviors (Ajzen, 1991), and can be applied to 
intentions to receive the vaccine. A major benefit of using the TPB is its history of being used in 
successful studies, many of which include sexual topics like condom usage (Bogart & Delhanty, 
2004). 
The Present Study 
 The purpose of the study is to examine intentions to receive the HPV vaccine among 
men. The present study will seek to use the TPB to model intentions to receive the HPV vaccine 
among young adult males. The HPV vaccine, Gardasil, has only been available since 2006, and 
most of the research currently published was done with data collected very near, or even before, 
the time when the vaccine became available. As such, with the majority of the HPV research 
literature focusing on women and their subsequent HPV risk, attitudes, and willingness to 
receive the Gardasil vaccine, additional research is warranted to address men as well. 
 Hypothesis 1: Males will have adequate variability in their intentions to receive the 
Gardasil vaccine. Past research that has evaluated males intentions has found adequate variability 
in questions that measure HPV vaccination intentions, willingness, and acceptance (e.g., Reiter 
et al., 2011; Daley et al., 2011; Daley et al., 2010). Daley and colleagues (2011) reported high 
intentions in to receive the Gardasil vaccine in the next 6 months (greater than 70% of the 
participants rated themselves as at least likely to receive the vaccine). Evaluating the skewness 
and kurtosis values for the intentions variable will statistically test this hypothesis.  These 
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skewness and kurtosis values are hypothesized to be less than |1.5|. If the values are greater than 
this, the score will be dichotomized so that the intentions variable represents those who intend to 
receive the HPV vaccine in 6 months, and those who do not intend to receive the HPV vaccine in 
3 months. 
 Hypothesis 2: As race has been inconsistently associated with intentions to receive the 
HPV vaccine, a one-way ANOVA will be performed to evaluate racial differences in intentions 
to receive the Gardasil vaccine. Bonferonni post hoc tests will evaluate main effects of racial 
differences. It is hypothesized that non-white individuals will have greater intentions to receive 
Gardasil. 
 Hypothesis 3: As intentions to receive the Gardasil vaccine have been shown to be 
different as a function of sexual orientation, a one-way ANOVA will be performed to evaluate 
differences in intentions to receive the vaccine among gay, bisexual, straight, and queer 
identified adults. It is anticipated that non-heterosexual identified participants will report greater 
intentions to receive the Gardasil vaccine. 
 Hypothesis 4: Past research suggests that individuals who have greater sexual partners 
report greater willingness to receive the Gardasil vaccine, as well as acceptance of the vaccine 
(Gerend et al., 2008; Jones & Cook, 2008; Ferris et al., 2009). As such, it is hypothesized that a 
spearmans rho correlation will reveal a significant positive correlation between number of sexual 
partners in the past 3 months and intentions to receive the Gardasil vaccine. 
 Hypothesis 5: As DiClemente and colleagues (2011) illustrate, something as simple as a 
commercial can increase intentions to receive the Gardasil vaccine among men. As such, it is 
hypothesized that those with who are highly influenced by Gardasil commercials will have 
significantly lower intentions to receive the Gardasil vaccine. 
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 Hypothesis 6: Attitudes towards HPV vaccination, perceived norms associated with HPV 
vaccination, and perceived behavioral control will all independently predict intentions to be 
vaccinated against HPV with the Gardasil vaccine. Furthermore, the TPB model will fit the data 
well, with a Root Mean Squared Error of Approximation (RMSEA) less than .05. The chi-square 
value for the overall model will not be significant, indicating that there is not a significant 
amount of unexplained variance in the model. The model will control for racial demographics, 
sexual orientation, and sexual behavior, as these factors have been associated with willingness to 
receive the Gardasil vaccine. 
 The postulated direction of relationships is as follows: those with more positive attitudes 
towards Gardasil will report greater intentions to receive the Gardasil vaccine. Those with more 
positive perceived norms will report greater intentions to receive the Gardasil vaccine. Those 
with greater perceived behavioral control will report greater intentions to receive the Gardasil 
vaccine. 
Method 
Procedure 
 Power analysis illustrated that with 10 predictors in the model, an n = 155 participants 
were sufficient to detect a small effect at .80 (80%). Participants were undergraduate psychology 
students who completed a survey online. Participants were given course credit for their 
involvement in this project. Participants were asked if they would like to complete a survey on 
sexually transmitted disease attitudes. Before participants began the survey, they completed an 
electronic informed consent that detailed that participation is voluntary and they could refuse to 
answer any questions that they are not comfortable answering. Only those who identified as male 
and between the ages of 18-26 were asked to participate. The present study was completely 
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anonymous and approved by the Institution Review Board (IRB) at Virginia Commonwealth 
University (VCU). 
Materials 
 Demographics. Participants were asked about their gender, sexual orientation, ethnicity, 
age, and relationship status. Gender was asked to ensure that only male identified participants are 
participating. The main purpose of asking about age was to ensure that participants fell between 
the ages of 18 and 26. 
Attitudes Towards HPV Vaccine. Attitudes towards HPV were measured using the 
“harms” subscales of the Carolina HPV Immunization Attitudes and Beliefs Scale (CHIAS; 
McRee et al., 2010). This subscale measured HPV attitudes and beliefs. The “harms” subscale 
contains 6 items (α = .69) and measures the degree to which individuals perceive the HPV 
vaccine to be harmful (e.g., “The HPV vaccine might cause lasting health problems.”). 
Responses ranged from 1 (Strongly Agree) to 4 (Strongly Disagree). In addition to these items, 
the present study utilized additional items to further examine the construct of attitudes, by using 
items borrowed from a sample TPB questionnaire (Ajzen, 2012), these items had responses 
ranging from 1 (Strongly Agree) to 4 (Strongly Disagree). These questions measured general 
attitudes towards the HPV vaccine. These measures will together estimate the construct of 
“Attitudes towards receiving the HPV vaccine”. Higher scores on these measures will represent 
more positive attitudes towards the HPV vaccine. Relevant items were reverse coded.  
Perceived norms. Perceived norms were measured with an aggregate of theoretically 
oriented items from a sample TPB questionnaire (Ajzen, 2012). An example of one of these 
items is “My parent would think it would be a good idea for me to receive the Gardasil vaccine.” 
Responses ranged from 1 (Strongly Agree) to 4 (Strongly Disagree). As perceived norms also 
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contain an evaluative component, participants were asked questions that measure how they 
evaluate their norms (e.g., “How much do you value your friends’ opinions in your decision to 
get the Gardasil vaccine?“). Responses ranged from 1 (Very Little) to 5 (Very Much).  
Perceived behavioral control. The “barriers” subscale of the CHIAS was combined with 
3 theoretically relevant items from Azjen’s TPB sample survey (Ajzen, 2012) to measure 
perceived behavioral control. This subscale contains 5 items (α = .69), plus 3 from Ajzen’s 
sample survey for a total of 8 items, and measures perceived ability to receive the HPV vaccine 
(e.g., “I am concerned that the HPV vaccine costs more than I can pay”), responses ranged from 
1 (Strongly Disagree) to 6 (Strongly Agree) or 1 (Not difficult at all) to 6 (Extremely Difficult) 
where appropriate. Control beliefs were measured also (e.g., “Unanticipated events would make 
it unlikely for me to receive the Gardasil vaccine”), responses ranged from 1 (Strongly Disagree) 
to 5 (Strongly Agree). Together, these two constructs together represent the latent construct of 
“Perceived behavioral control towards receiving the HPV vaccine”. For perceived self-efficacy, 
higher scores represent greater efficacy towards receiving the HPV vaccine. For perceived 
controllability, higher scores represent less controllability towards receiving the HPV vaccine.  
Sexual behavior. Participants were asked to report the number of sexual partners that 
they had in the past 3 months. Research has demonstrated that individuals who are sexually 
active are more willing to receive the Gardasil vaccine (Gerend et al., 2008; Jones & Cook, 
2008; Ferris et al., 2009; Crosby et al., 2012).  
Media influence. Participants were asked two types of questions, the first type measured 
media influence from the HPV vaccine commercials, such as “Seeing the Gardasil commercials 
on TV make me feel like I shouldn’t get the vaccine.”. The second type of question measured 
general use of media for health information, by asking questions such as “How often do you use 
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the Internet/Radio/Television for health information?”. Similar questions have been used in past 
research (Ben-Zur et al., 2012). Responses ranged from 1 (Strongly Disagree) to 5 (Strongly 
Agree) and 1 (Not at all often) to 5 (Very often) for each question where appropriate. Each item 
included the option to opt out due to non-exposure (e.g., “N/A, I have not seen a Gardasil 
commercial.”). Higher scores on this measure indicate greater influence from the media when 
deciding to vaccinate with the HPV vaccine. 
HPV vaccination intention. Behavioral intention was measured with a single item 
“There is a vaccine available that can protect you against HPV (e.g., Gardasil), to what degree do 
you intend to receive this vaccine within the next 6 months?” Responses ranged from 1 (Not at 
all likely) to 4 (Very likely). Items similar to this have been used in past research (e.g., Daley et 
al., 2011). Higher scores on this item represent greater intention to receive the HPV vaccine. 
Data Analysis 
 As the present research used measures constructed for the purposes of this specific study, 
factor analysis was performed on all scales used in this study. Reliabilities were also checked for 
each sub-factor, and items that load onto both factors will be deleted so as to have a goal 
Cronbach’s alpha above .70.  
 One-way ANOVAs were performed to test differences in sexual orientation as well as 
racial differences in intentions to receive the HPV vaccine. Tukey post-hoc tests were performed 
to confirm significant mean differences between these groups. 
 Spearman’s rho correlation tested the hypothesis that greater sexual frequency (defined as 
the number of sexual partners in the past 3 months) will be associated with greater intentions to 
receive the HPV vaccine. It is expected that those with greater sexual frequency will report 
greater intentions to receive the HPV vaccine. 
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 Pearson’s r correlations were performed to examine the relationship between media 
influence and intentions to vaccinate.  
 The TPB posits that normative beliefs, attitudes towards the behavior, and perceived 
behavioral control will predict behavioral intentions (Azjen, 1991). Figure 1 illustrates the 
hypothesized structural equation model of vaccination intentions. This model was tested using 
AMOS software version 20. 
 
Figure 1. Proposed structural equation model to test the theory of planned behavior. 
Data Quality Assurance 
 Participants who reported already having received the HPV vaccine were eliminated (n = 
41), leaving a final sample size of n = 226. As sample size was small, and many parameters are 
being estimated, a Bollen-Stine bootstrap was performed to correct for small sample size (n = 
500 samples). Reliability analyses (Cronbach’s α) and exploratory factor analyses were 
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performed to eliminate potentially poorly worded or poor fitting items to the respective 
constructs being measured. An additional benefit of these procedures was to ensure adequate 
power, and to further reduce the amount of parameters estimated given the relatively small 
sample size (n = 226). There were no missing values in the present dataset, so the full sample 
size of 226 was retained throughout the analysis. Analyses were performed with AMOS version 
20 and SPSS version 20. 
Results 
 The sample consisted of 50.6% White identified individuals, 18.3% African-American, 
7.2% Hispanic/Latino, 17.4% Asian American, and 6.4% identified as “Other”. Average age was 
19.23 (SD = 1.78). Most of the sample consisted of students in their freshman year of college 
(62.1%), with 19.1% identifying as sophomore, 12.3% as Junior, 6.0% as Senior, and .4% (n = 1) 
as in their 5
th
 year. Most of the sample (92%) identified as heterosexual, with 1.8% identified as 
bisexual, and 6.2% identifying as gay/homosexual. 
 Hypothesis 1  
 Normality of the vaccination intentions item was examined using skewness and kurtosis 
statistics. As a general rule of thumb, skewness and kurtosis less than |1| suggest a normal 
distribution. Results indicate that the HPV vaccination intention item was normally distributed 
(Skewness = .052, SE = .16), (Kurtosis = -.638, SE = .32), M = 2.42, SD = .86; Range: 1 – 4. 
 Hypothesis 2 
 The second hypothesis was to evaluate racial differences in the intentions variable. A 
one-way ANOVA as performed on the intentions to receive the HPV vaccine variable, which 
indicated significant variability as a function of race F(4, 221) = 4.45, p = .002. Tukey post-hoc 
tests indicated that the only significant racial difference was that between Whites (M = 2.27, SD 
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= .87) and those who identified themselves in the “Other” category (M = 3.0, SD = .56), p = .02. 
This indicates that those who identified as “Other” in their racial category had significantly 
greater intentions to receive the HPV vaccine than did Whites. All other racial comparisons were 
performed, and were not significant (p’s > .05; Figure 2). 
 
Figure 2. Means of HPV vaccination intention among different races. 
Hypothesis 3 
 The third hypothesis examined how sexuality was associated with HPV vaccination 
intentions. A one-way ANOVA was performed to examine differences in HPV vaccination 
intentions among those who identified as straight (heterosexual; n = 208), bisexual (n = 4), gay 
(Homosexual; n = 14). Results indicated that there was no effect of sexuality on HPV 
vaccination intentions F(2, 223) = 0.85, p = .43. The simple means for gay (M = 2.42, SD = .86) 
and bisexual men (M = 2.75, SD = .86) were slightly higher than that of heterosexual men (M = 
2.39, SD = .87), but not outside the range of sampling error. See Figure 2 for a visual 
representation of the means. 
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 Due to this small sample sizes per cell for sexual orientation, Cohen’s d effect sizes for 
the mean differences were computed. Cohen’s guidelines suggest that a value of .2 is small, .5 is 
moderate, and .8 is large in effect. The difference between gay and heterosexual men yielded a 
Cohen’s d value of .04, and the difference between heterosexual and bisexual men yielded a 
Cohen’s d value of .42. This suggests that the mean differences between heterosexual and 
bisexual men indicated a small effect, while the differences between heterosexual and 
homosexual men had effects that did not even reach the threshold of “small” (.2). As only 4 total 
participants identified as bisexual, a dummy variable was created to compare heterosexual vs. 
non-heterosexual individuals in their intentions to receive the HPV vaccine. Results indicate no 
statistically significant difference in vaccination intentions, t(224) = -1.29, p = .20, d = .34, but a 
small effect size of the mean differences between the two groups. 
 
Figure 3. Means of HPV vaccination intentions among different sexual orientations. 
Hypothesis 4 
 The fourth hypothesis was to examine the relationship between number of sexual partners 
and intentions to receive the HPV vaccine. Results suggest that there is no relationship between 
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the number of sex partners in the past 3 months and intentions to receive the HPV vaccine 
rs(223) = -.06, p = .36.  
 Hypothesis 5 
 The fifth hypothesis examined the impact of media influence on HPV vaccination 
intentions. Given that a “NA” option was added to each question, a total of n = 117 people were 
deleted from analysis for answering “no” to any question. This left a total of 118 participants to 
analyze responses for media influence. An exploratory factor analysis was performed using 
principal components analysis as an extraction technique and varimax rotation as a rotation 
technique. Results indicated two factors that were indicated a priori. The first factor was media 
influence [eigenvalue = 3.89, R
2
 = 35.35, α = .88] and, the second factor was use of the media for 
health information [eigenvalue = 1.92, R
2
 = 17.41, α = .62], see Table 1 for factor loadings. As 
all items clearly loaded onto their respective factor, no items were deleted. Simple correlations 
revealed that media influence was not associated with HPV vaccination intentions in men r(116) 
= .15, p = .10. There was also no significant relationship between use of media for information 
and HPV vaccination intentions r(116) = .02, p = .86. As there was no relationship between 
media influence and vaccination intentions, the decision was made to use the full sample size of 
226 for the test of hypothesis 6. 
 
 
 
 
Table 1. 
Factor loadings for the media influence items 
Media Influence Items. Factor 
loading 
Factor 
loading 
Mean (SD) 
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(Factor 1) (Factor 2) 
1. Seeing the Gardasil 
commercials on TV make me feel 
like I shouldn’t get the vaccine. 
.886 -.070 4.11 (1.68) 
2. Seeing the Gardasil 
advertisements in magazines 
make me feel like I shouldn’t get 
the vaccine. 
.921 -.092 4.34 (1.68) 
3. Seeing the Gardasil 
advertisements in other print 
media makes me feel like I 
shouldn’t get the vaccine. 
.918 -.077 4.31 (1.70) 
4. I feel like HPV is not a concern 
for me because of the Gardasil 
commercials on TV. 
.918 -.036 4.09 (1.72) 
5. The information that I learned 
about Gardasil on the Internet 
makes me not want to get the 
vaccine. 
.896 -.102 4.25 (1.72) 
6. The information that I learned 
about Gardasil on the news makes 
me not want to get the vaccine. 
.911 -.133 4.22 (1.76) 
7. I value what the Gardasil 
commercials on TV have to say. 
.849 .007 4.04 (1.75) 
8. The Gardasil commercials on 
TV are very informative to me. 
.839 .023 3.99 (1.76) 
9. How often do you use the 
Internet for health information? 
.055 .607 2.89 (1.26) 
10. How often do you use the 
Television for health information? 
-.023 .895 1.87 (1.00) 
11. How often do you use the 
Radio for health information? 
-.226 .747 1.50 (0.87) 
 
 Hypothesis 6: Theory of Planned Behavior Model for Predicting HPV Vaccination 
  Exploratory Factor Analysis 
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To estimate the latent constructs in the structural equation model, indicators were created 
from the scale items presented in the methods section. Exploratory factor analyses were 
performed on all scales in this study to eliminate flawed items. Principal components analysis 
was utilized as an extraction technique, and varimax rotation was performed as a rotation 
technique. The decision was made to retain items with factor loadings above .60. 
The attitudes towards vaccination measured loaded onto a single factor [eigenvalue = 
3.70, R
2
 = .62; α = .87]; as such, all 6 items were retained in estimating the latent construct of 
attitudes towards HPV vaccination (Table 2).  
Table 2. 
Factor loadings for the attitudes towards HPV vaccine items. 
Attitudes towards HPV vaccine items. Factor 
loading 
Mean (SD) 
1. The HPV vaccine might cause short-term problems, 
like fever or discomfort. 
.753 3.80 (1.21) 
2. The HPV vaccine is being pushed to make money for 
drug companies. 
.832 3.48 (1.49) 
3. The HPV vaccine might cause lasting health 
problems. 
.825 3.77 (1.36) 
4. If a teenage girl gets the HPV vaccine, she may be 
more likely to have sex. 
.774 3.28 (1.58) 
5 I think the HPV vaccine is unsafe. .787 3.53 (1.54) 
6. Adolescent girls are too young to get a vaccine for 
sexually transmitted infections, like HPV. 
.737 2.90 (1.58) 
 
The behavioral beliefs measure was submitted to factor analysis and revealed that 1 item 
loaded onto a separate factor; this item was subsequently removed from analysis, leaving a 4-
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item measure of behavioral beliefs [eigenvalue = 2.65, R
2
 = .53; α = .80]. See Table 3 for the 
factor loadings of these items. A strikethrough indicates that that respective item was deleted. 
Table 3. 
Factor loadings for the behavioral beliefs items 
Behavioral Beliefs Items. Factor loading 
(Factor 1) 
Factor loading 
(Factor 2) 
Mean (SD) 
1. The Gardasil vaccine would be a good 
health decision on my part. 
.775 .180 3.26 (0.88) 
2. Getting the Gardasil vaccine would 
protect my future sex partners from HPV. 
.798 .037 3.37 (0.98) 
3. Getting the Gardasil vaccine would 
help me to learn more about sexually 
transmitted infections. 
.734 .128 3.26 (0.96) 
4. The Gardasil vaccine would make me 
feel uncomfortable. 
.155 .984 3.16 (1.01) 
5. Getting the Gardasil vaccine would 
help me to be healthier. 
.808 .174 3.20 (0.90) 
 
An identical factor analysis was performed on the perceived norms items, which loaded 
onto three factors with an eigenvalue ≥ 1. The second and third factors had multiple items cross-
loading onto one another, suggesting that these items may be potentially poorly worded or 
uncorrelated with other items in the scale; those items were removed from analysis. This resulted 
in a 4-item measure that clearly loaded onto one factor to estimate the latent construct of 
perceived norms [eigenvalue = 2.89, R
2= .72; α = .87] Table 4 indicates the factor loadings for 
the norms measure. 
 
Table 4.  
Factor loadings for the perceived norms items. 
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Perceived Norms Items. Factor loading 
(Factor 1) 
Factor loading 
(Factor 2) 
Factor loading 
(Factor 3) 
Mean (SD) 
1. My mother would 
think it would be a good 
idea to receive the 
Gardasil vaccine. 
.888 .006 -.004 3.16 (0.98) 
2. My father would think 
it would be a good idea 
to receive the Gardasil 
vaccine. 
.857 -.087 .120 3.14 (0.91) 
3. My parent would 
think it would be a good 
idea to receive the 
Gardasil vaccine. 
.891 -.132 .090 3.19 (0.91) 
4. I think my friends 
would support my 
getting the Gardasil 
vaccine. 
.557 -.482 .143 3.20 (0.85) 
5. I think that Gardasil is 
just for girls. In general, 
I think that the people of 
Virginia would not 
support me getting the 
Gardasil vaccine. 
-.030 .848 .011 2.77 (0.90) 
6. People who are 
important to me would 
not support me in 
getting the Gardasil 
vaccine. 
-.558 .542 .204 2.62 (0.92) 
7. I know other men 
who have received the 
Gardasil vaccine. 
.019 .312 .815 2.26 (1.01) 
8. The people whose 
opinions I value most 
would think it is a good 
idea for me to get the 
Gardasil vaccine 
.613 -.363 .269 3.07 (0.95) 
9. I value what the 
Gardasil commercials on 
.185 -.364 .763 2.78 (0.86) 
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television tell me. 
 
 The 3-item measure for motivations to comply with norms were next entered into a 
factor analysis, and the 3 items clearly loaded onto the one factor. As such, all 3 items were 
retained to estimate motivations to comply with norms [eigenvalue = 2.46, R
2
 = .49; α = .85] 
Table 5 shows the factor loadings and items for this measure.  
Table 5.  
Factor loadings for the motivations to comply with norms items. 
Motivations to comply with norms items. Factor loading 
(Factor 1) 
Factor loading 
(Factor 2) 
Mean (SD) 
1. How much do you value your parents' 
opinion in your decision to get the 
Gardasil vaccine? 
.880 -.032 2.93 (1.41) 
2. How much do you value your friends’ 
opinion in your decision to get the 
Gardasil vaccine? 
.912 -.026 3.18 (1.34) 
3. How much do you value the internet’s 
opinion in your decision to get the 
Gardasil vaccine? 
.829 .254 2.75 (1.23) 
 
The final factor analysis examined the measure of perceived behavioral control. Dimension 
reduction revealed that 2 items loaded onto a second factor, and those items were subsequently 
removed from analysis, leaving 6 items (Table 6) to estimate the latent construct of perceived 
behavioral control [eigenvalue = 2.68, R
2
 = .54; α = .78].  
Table 6. 
Factor loadings for the perceived behavioral control items. 
Perceived Behavioral Control Factor loading 
(Factor 1) 
Factor loading 
(Factor 2) 
Mean (SD) 
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1. Getting the Gardasil vaccine 
would be easy for me. 
.718 .232 3.21 (0.93) 
2. It would be a good idea to get the 
Gardasil vaccine. 
.622 .364 3.14 (0.85) 
3. Whether or not I get the Gardasil 
vaccine is completely up to me. 
.704 -.149 3.93 (1.13) 
4. If I really wanted to, I know I 
could get the Gardasil vaccine. 
.744 .129 3.63 (1.05) 
5. It is expected that I get the 
Gardasil vaccine. 
.078 .784 2.47 (0.93) 
6. I will make an effort to get the 
Gardasil vaccine 
.031 .808 2.67 (0.95) 
7. It would be difficult for me to get 
the Gardasil vaccine. 
.631 -.213 2.43 (0.93) 
8. I am confident I can find a place 
to receive the Gardasil vaccine. 
.804 .148 3.53 (1.02) 
 
Control beliefs loaded onto one factor [eigenvalue = 1.63, R
2
 = .54; Table 7], but did not 
have adequate Cronbach’s alpha values (α = .58), and were removed from further analysis. Even 
though control beliefs (which are theoretically part of the construct of perceived behavioral 
control) were not adequately measured in this study, it is worth noting that many tests of the TPB 
often substitute self-efficacy for perceived behavioral control (Gerend & Shepherd, 2012). 
Table 7. 
Factor loadings for the perceived controllability items. 
Perceived Controllability Factor 
loading 
Mean (SD) 
1. Unanticipated events would make it unlikely for me 
to get the Gardasil vaccine. 
.634 2.94 (0.91) 
2. If I didn’t feel well, I would make it more difficult to 
get the Gardasil vaccine. 
.785 3.08 (0.89) 
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3. If my job or coursework put too many demands on 
my time, it would make it difficult for me to get the 
Gardasil vaccine. 
.785 3.15 (0.96) 
 
The means and standard deviations for all final scales are shown in Table 8. 
Table 8. 
Means and standard deviations of all constructs measured. 
Construct Mean (SD) 
Media Beliefs 39.61 (12.23) 
Attitudes Towards HPV 20.75 (6.88) 
Behavioral Beliefs 10.91 (2.92) 
Perceived Norms 12.55 (3.18) 
MTC Norms 8.86 (3.50) 
Perceived Behavioral Control 19.88 (3.37) 
 
Structural Equation Model 
Structural equation modeling was performed using maximum likelihood estimation to test 
the overall fit of attitudes towards HPV vaccination, HPV vaccination norms, and perceived 
behavioral control over HPV vaccination as predictors of HPV vaccination intentions. Structural 
equation modeling allows a researcher to compare a tested model’s observed variance/covariance 
matrix to an implied variance/covariance matrix (e.g., the theory of planned behavior model), 
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which allows for a test of how well the theoretical model fits the given data.  Results from the 
structural equation model are presented in Figure 4.  
 
Figure 4. Structural equation model of the theory of planned behavior 
To understand the unique impact of the separate TPB constructs (e.g., behavioral beliefs 
vs. general attitudes), separate latent constructs were estimated for each, and were correlated 
with each other in the final model. The data were not multivariate normal (Mardia’s coefficient = 
131.76 ≥ 31.08), however as a Bollen – Stine bootstrap procedure was performed, this non-
normality should not bias the results of the structural equation model. The model provided 
adequate overall fit to the data [Bollen - Stine χ2 = 341.30, df = 195, p = .02, CFI = .934, TLI = 
.922, RMSEA = .057]. The significant χ2 value indicates a misspecification in the comparison of 
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the observed and reproduced variance/covariance matrix. However, the CFI and TLI values were 
both above .90, with an RMSEA confidence interval containing a lower end value less than .05 
(90% RMSEA CI: .047, .066). Considering these fit statistics, we argue that the TPB provides an 
adequate overall fit to the data. The model indicated many significant correlations among the 
latent predictors of HPV vaccination intentions. These correlations are presented in Table 9.  
Table 9.  
Correlations among the latent constructs. 
Latent Construct   BehBeliefs Attitudes Norms  MTC  PBC  
1. BehBeliefs      1          
 
2. Attitudes   -.09                1    
 
3. Norms    .62***     -.18*     1   
 
4. MTC     .18*                   -.10    .07      1   
 
5. PBC     .38***     -.14    .36***   .08      1 
______________________________________________________________________________ 
Standardized covariance estimates among latent predictors in the model  
Note: BehBeliefs = Behavioral beliefs, MTC = Motivations to comply with norms, PBC = 
Perceived behavioral control 
N = 235. *p < .05, ***p < .001 
 
 There were significant correlations between norms and behavioral beliefs, indicating that 
those who perceived greater social norms towards HPV vaccination were more likely to feel that 
vaccination would produce a beneficial outcome (r = .62, p < .001). Norms were also negatively 
correlated with attitudes towards HPV vaccination, suggesting that those who had negative 
attitudes towards HPV vaccination perceived HPV vaccination as less normative (r = -.18, p = 
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.02). Motivations to comply with norms did not correlate with perceived norms (r = .07, p = .37), 
supporting the notion that norms and motivations to comply with those norms are separate 
constructs. However, motivations to comply with norms were positively associated with 
behavioral beliefs (r = .18, p = .02). This indicates that that those who value norms about HPV 
vaccination may in turn believe that vaccination will produce a favorable outcome for them. 
 In the final model, perceived behavioral control was not associated with intentions to 
vaccinate with the HPV vaccine; perceived behavioral control was, however, positively 
associated with both behavioral beliefs (r = .38, p < .001) and perceived norms (r = .36, p < 
.001). These results indicate that those who perceived greater social norms towards HPV 
vaccination were also more likely to see vaccination as more normative. With the full model 
being estimated with adequate fit, the parameters indicate that the sole predictor of intentions to 
receive the HPV vaccine in the next 6 months was behavioral beliefs [β = .288, p = .005]. 
Exploratory Analyses: HPV vaccination 
 Exploratory analyses were performed to examine demographic differences in those who 
have received the HPV vaccine. Out of the 267 participants who completed the survey, 26 
(9.7%) stated that they received the HPV vaccine when asked the question “Have you ever 
received the Gardasil vaccine?”  
 A chi-square analysis was performed to examine if there were racial differences in those 
who received the HPV vaccine, for which there were no differences observed χ2 = 5.64, df = 4, p 
= .23. Furthermore, gay and bisexual men did not differ from heterosexual men in terms of 
having already received the HPV vaccine χ2 = 0.49, df = 2, p = .78. When relationship status was 
submitted to a chi-square analysis, no differences emerged between persons in a relationship or 
single, χ2 = 2.02, df = 3, p = .57. An additional question that simply asked “Are you sexually 
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active?” was used in a chi-square analysis to examine differences between having been 
vaccinated with Gardasil or not, to which no differences emerged, χ2 = 0.83, df = 2, p = .66. An 
exploratory question asked participants if any person in their family had ever had cancer, with 
56.9% indicated “yes”, 32.6% indicating “no”, 10.5% indicating “do not know”. Those who 
indicated a family history of cancer were significantly more likely to report having received the 
HPV vaccine (13.8%) than those who did not report such family history (5.7%), χ2 = 7.47, df = 2, 
p = .02, in addition to indicating “false” on a question that stated “HPV is a woman’s disease” 
(response options were true, false, or don’t know), χ2 = 11.07, df = 4, p = .03. The question 
examining HPV as a woman’s disease, however, was unrelated to intentions to receive the HPV 
vaccine among the unvaccinated, F(2,264) = 0.82, p = .92. 
Discussion 
The present study was the first to my knowledge to test the TPB in relation to male HPV 
vaccination with all of its correct theoretical predictors. Result from this study furthers the 
understanding of male intention to receive the HPV vaccine.  
Hypothesis 1: Normality 
 The first hypothesis examined the normality of vaccination intentions. Given that HPV 
vaccination is relatively new for men, there are concerns that there may be a lack of normality in 
intentions to receive the HPV vaccine. Results from this study showed that the HPV vaccination 
item was normally distributed, and furthermore provide support for past research which has 
found significant results while using similar HPV vaccination items (Reiter et al., 2011; Daley et 
al., 2011; Daley et al., 2010). 
Hypothesis 2: Race 
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 The second hypothesis sought to examine racial variability in intentions to receive the 
HPV vaccine. The test results suggest that the only difference observed was between white and 
“other” races. With only 6.4% of the sample identifying as “Other” race, these differences are 
difficult to interpret. Pragmatically, they mean that those who identified as “Other” had greater 
intentions towards receiving the HPV vaccine than whites. This means that those who may be 
mixed race or identify as an unmeasured race in this study have greater intentions towards 
receive the HPV vaccine in the next 6 months.  
 Research has documented what is called the “White male effect” (Finucane, Slovic, 
Flynn, & Satterfield, 2000), which posits that White males tend to perceive their subjective risk 
as lower than that of non-whites. This “White male effect” defines risk perception more 
generally, but can be applied to the results herein. While there were no differences in HPV 
vaccination intentions among the other races measured (e.g., African-American, Hispanic, 
Asian-American), the differences between Whites and “other” races may support the White male 
effect in this instance.  
Hypothesis 3: Sexual Orientation 
 The third hypothesis was to examine differences in vaccination intentions as a function of 
sexual orientation. Past research suggests that gay and bisexual men have more positive attitudes 
towards the HPV vaccine (Gilbert et al., 2011b), and greater knowledge about HPV, as well as 
greater perceived likelihood of contracting HPV (Gilbert et al., 2011b). Results from this sample 
do not support the hypothesis that there are differences in vaccination intentions between sexual 
orientation groups. While gay and bisexual men had slightly higher means than heterosexual 
men, these means were not statistically different from the means of the heterosexuals in this 
sample. These results should be interpreted cautiously due to a low variability in sexual 
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orientation in our sample. Only 8% of our unvaccinated sample identified as gay or bisexual, and 
with the large number of individuals identifying as straight, there may not have been enough 
power to detect differences in intention to receive the HPV vaccine.  
 To further investigate this issue of small variability in sexual orientation, the Cohen’s d 
values indicated that the difference between bisexual and heterosexual men indicated a small 
effect (.42 > .2), which suggests that bisexual men may have greater intentions to receive the 
HPV vaccine when compared to heterosexual men. The effect size for the differences between 
gay and heterosexual men did not reach the threshold of .2, so the assumption remains that gay 
men and straight men are similar in their intentions to receive the HPV vaccine. When gay and 
bisexual men were combined into one category, there was a small effect of the mean difference 
between the two groups (d = .34), resulting in non-heterosexuals (gay and bisexual men) 
potentially having greater intentions to receive the HPV vaccine when we consider the effect 
size. 
Hypothesis 4: Sexual Behavior 
 Past research has shown that having more sexual partners is associated with greater 
willingness to receive the HPV vaccine, and a greater acceptance of that vaccine (Gerend et al., 
2008; Jones & Cook, 2008; Ferris et al., 2009). No past research to our knowledge has examined 
how sexual behavior is associated with intentions to receive the HPV vaccine. However, past 
research has identified positive relationships between sexual behavior and willingness to receive 
the vaccine, as well as acceptance of the vaccine. Results from the present study showed that the 
spearman’s rho correlation between the number of sexual partners in the past 3 months and HPV 
vaccination intentions was not statistically significant. Furthermore, our exploratory analysis that 
examined if sexually active individuals were significantly more likely to already have received 
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the vaccine was not significant. Given that acceptance and willingness to receive the HPV 
vaccine may be a completely separate construct from actual intention to receive the vaccine 
could explain this non-significant result. However, it would be reasonable to assume that 
willingness and acceptance would be highly correlated. Given that intentions involve a specific 
behavioral component, intentions may represent a conceptual departure from constructs like 
acceptance and willingness to receive the vaccine. As multiple studies have established a 
relationship between sexual behavior and HPV vaccine willingness/acceptance, the remaining 
explanation could be that men who have greater sexual partners may very well be willing to 
receive the HPV vaccine, and think that getting the vaccine is acceptable, but may not actually 
want to put the effort into getting the vaccine for themselves. 
 This result provides fruitful areas for future research, as there may be many different 
statistical results when framing questions about HPV vaccination intention. Whether or not 
someone accepts a vaccine, or is willing to receive it, may not indicate that they are intending to 
receive the vaccine. Intentions require an active action on the part of the behavioral agent (the 
individual), and may therefore be a different construct. 
Hypothesis 5: Media influence 
 The research examining media influence on HPV vaccination intentions in males is 
scarce. Results from the present study suggest that both influence from HPV commercials, as 
well as using media for health information, were uncorrelated with intentions to receive the HPV 
vaccine. DiClemente and colleagues (2011) provided initial support for this hypothesis when 
their experiment on media influence indicated that any type of media advertisement targeting 
men increased male intentions to receive the HPV vaccine. This could bolster the argument that 
HPV vaccination may be more normative now, and that men may no longer see the HPV vaccine 
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as a “Women’s issue” as a result of media advertisements heavily focusing on women. However, 
more recent advertisements have been geared towards men and participants in this study may 
have been exposed to those. 
Hypothesis 6: TPB Model 
Using our combination of CHIAS measures (McRee et al., 2010) and items modeled after 
a sample TPB survey (Ajzen, 2012), the TPB provided an adequate fit to the data. One curious 
finding that arose in examining the correlations among the latent constructs in the model was that 
perceived behavioral control was correlated with perceived norms and behavioral beliefs in such 
a way that suggests greater belief that getting the HPV vaccine would produce favorable 
outcomes, along with greater perceived norms towards receiving the HPV vaccine, were 
associated with greater perceived ability to receive the HPV vaccine. These relationships are all 
in the expected directions. Of note is the especially strong relationship between behavioral 
beliefs and perceived norms. The beta coefficient was .62 (p < .001), suggesting that men who 
perceive greater norms of HPV vaccination are more likely to believe that it is beneficial for 
them to receive the vaccine. 
Other interesting results from the correlations among the TPB predictors illustrate that 
norms and behavioral beliefs are highly correlated. This illustrates that norms and behavioral 
beliefs may affect each other, such that those who perceive HPV vaccination as more normative 
may also believe that HPV vaccination will produce favorable outcomes, or vise-versa. A weak 
relationship was found between norms and attitudes, suggesting that those with greater perceived 
HPV vaccination norms had less negative attitudes towards HPV vaccination. Moreover, an 
equally weak relationship was found between motivations to comply with norms and behavioral 
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beliefs, suggesting that those who value social norms in general are more likely to believe HPV 
vaccination will produce a favorable outcome for them. 
The model illustrated that the sole predictor of intentions to receive the HPV vaccine was 
behavioral beliefs. Again, behavioral beliefs represent the idea that engaging in a behavior (in 
this case, vaccination with the HPV vaccine) will produce a favorable given outcomes (e.g., 
protecting other partners, making oneself more healthy, etc.). This would indicate that the most 
powerful predictor of whether a male vaccinates with the HPV vaccine would be whether he 
believes doing so would be a good idea for his personal health. While surprising that no other 
predictors on the TPB model were significant, it may make sense given that this sample 
contained all men. Men are often not the targets of HPV vaccine advertisements, and the CDC 
has only recently recommended that men receive the vaccine. As such, perceived norms towards 
male vaccination may simply not be established yet among this sample. As a potential result of 
this, motivations to comply with norms were also not a significant predictor of intentions to 
receive the HPV vaccine. Attitudes toward HPV vaccination were measured using a previously 
validated measure (the CHIAS; McRee et al., 2010), which theoretically mapped onto attitudes 
towards HPV vaccination. This relationship between attitudes towards HPV vaccination and 
intentions to receive the HPV vaccine was not significant, which may illustrate that men simply 
may not utilize how they feel about the HPV vaccine when making judgments as to whether or 
not they will receive the vaccine. Interestingly enough, Gerend & Shepherd (2012) found the 
exact same beta coefficient for attitudes towards vaccination in their SEM model of the TPB 
with women [β = .09, p < .05], which may suggest that there is an effect of attitudes on 
vaccination intentions, but our sample size precluded us from detecting it. Alternatively, men 
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may see behaviors like vaccination as generally necessary and may not care about whether or not 
they have negative attitudes towards this specific health behavior.  
The final construct of the TPB model that did not significantly predict HPV vaccination 
intentions was perceived behavioral control. It may at first remain relatively puzzling that this 
factor did not predict HPV vaccination intentions, especially as perceived behavioral control 
tends to be among the strongest predictors in most TPB models (e.g., Gerend & Shepherd, 2012; 
Norman & Cooper, 2011). A study by Crosby and colleagues (2011) found that self-efficacy to 
be vaccinated with the HPV vaccine was not predictive of intentions to receive the vaccine. 
Furthermore, a study by Hernandez and colleagues (2010) included a variable in their analysis of 
male HPV vaccination intentions that asked participants whether transportation to a clinic to 
receive the vaccine would influence intentions; this also was not significant in their final 
analysis. Along with the results of the present study, it may suggest that perceived behavioral 
control may not be a crucial factor in predicting HPV vaccination intentions among men. The 
TPB argues that whether or not an individual engages in a health behavior is dependent on 
whether one believes one is able to engage in that behavior (Ajzen, 2002). The alternative 
explanation would be that whether or not a man believes he is able to get the HPV vaccine is 
irrelevant in the subsequent intentions to receive the HPV vaccine. The perception of vaccination 
may be different from that of other health behaviors, like quitting smoking or negotiating safer 
sex. Receiving the HPV vaccine may be perceived as relatively easy, and so an immense amount 
of self-efficacy may not be needed to actually intend to receive it. 
Exploratory analyses 
 Our exploratory analyses were performed to examine demographic factors that were 
associated with having already received the HPV vaccine. These results suggest that no one 
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demographic factor predicted HPV vaccination: sexual orientation, race, sexual activity, and 
relationship status. The sole demographic factor that was predictive of HPV vaccination was 
having a family history of cancer. This result ties in well with the results of the structural 
equation model, which suggests that behavioral beliefs are the sole predictor of HPV vaccination 
intentions. Those who have a family history of cancer may be high in the behavioral belief that 
vaccination will benefit them, because the perceived threat of them getting cancer at some point 
in the future is high.  
 Previous research on family histories of cancer has illustrated that women with a family 
history of cancer are more likely to receive a pap test (Williams, Reiter, Mabiso, Maurer, & 
Paskett, 2009). In this study, just having a family history of cancer was powerful enough for 
these women to receive a pap test, which is important for HPV detection. A similar finding was 
found in a male sample for prostate, colorectal, and skin cancer screenings. Shah and colleagues 
(2007) found that men who had a family history of prostate, colorectal, and skin cancer were 
significantly more likely to report receiving an examination coinciding with their family history; 
these results were stronger for young men.  
 Past research shows that there is a powerful impact of having a family history of cancer 
in terms of engaging in preventative measures to reduce the risk of cancer. Much in the same 
way, our data support these studies by showing that young men with a family history of cancer 
were more likely to report receiving the HPV vaccine. These vaccination behaviors could be 
potentially due to a doctor’s suggestion, or increased knowledge about HPV. The latter may be 
true given that men in this study who had a family history of cancer were also significantly more 
likely to indicate “false” on a question that stated “HPV is a woman’s disease”, suggesting that 
those who have been vaccinated may be more knowledgeable about male HPV risks. 
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Limitations 
 The present study had several limitations. Of these were cross-sectional data precluding 
any ability at causal inference. Secondly, the data presented in this study did not actually record 
whether or not participants received the HPV vaccine at a later time, which may have very well 
occurred and limits the full examination of the TPB model.  
 One major limitation in this study was that testing the TPB requires the researcher to 
create items to test the appropriate constructs. As such, the items used to test the most of the TPB 
model were created for the purpose of testing the TPB model. To make this process more 
stringent and nested within past studies, we often looked to past research to find appropriate 
constructs (e.g., using the CHIAS to estimate some constructs of the TPB, and a sample 
questionnaire). While EFA was performed to retain the best fitting items, it could be argued that 
a sample-specific model was fit and estimated based on EFA item retention.  
 While that may be true when estimating factor fit per construct (e.g., perceived norms, 
attitudes towards vaccination separately), it is not entirely plausible when testing the full 
theoretical model. This is due to items not being deleted based on poor factor loading when 
testing the full structural equation model, but when estimating each individual factor. As items 
were not retained to maximize the final model fit in the final model, but were deleted while 
performing a factor analysis on each individual construct before testing the final model, it 
provides a relatively stringent way of testing model fit in a single cross-sectional sample.  
This study employed a relatively small sample size. Through factor analysis we 
eliminated poorly fitting items, which reduced needless parameter estimates, and improved 
power. Moreover, the use of a Bollen – Stine bootstrapping technique corrects for small sample 
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size and non-normality, which should eliminate any negative impact of a small sample size when 
testing the full model. 
 The model that we posit only had adequate fit, as the RMSEA value was greater than .05. 
The chi-square statistic was significant, indicating a significant misspecification of the observed 
and reproduced variance/covariance matrix. Furthermore, the CFI and TLI values were above 
.90, but less than .95, which indicate adequate fit. Finally, the RMSEA value was greater than the 
suggested .05 cutoff value. However, since the 90% confidence interval contained .05 as an 
estimate of model fit, it is presumptuous to reject the model altogether.  
 The data from the current sample were derived from a majority (50.6%) white sample, 
which may preclude extrapolation of interpretation beyond this group. Post hoc analysis revealed 
that there were no significant differences between whites and non-whites in their intentions to 
receive the HPV vaccine in the next 6 months. 
General Implications 
While this study had limitations, it also provides insight into how the TPB fits when 
predicting college-aged male’s HPV vaccination intentions. An implication of the present study 
is that theoretical models may not work best when predicting health behaviors (e.g., vaccination) 
which may not be viewed as necessary or essential by certain groups (e.g., men); therefore, 
testing theoretical models may not provide the best predictors of behavior in populations who do 
not see themselves at risk. Future studies should consider performing comparisons of theoretical 
models of HPV vaccination between genders. As found by Gerend and Shepherd (2011), the 
TPB was a fitting model for predicting HPV vaccination intentions for female participants, 
outperforming the HBM in terms of model fit. The present research suggests that males may be 
different from females in terms of how they decide on whether or not to receive the HPV 
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vaccine. As such, a specific avenue for future research would be to test and compare models of 
behavior change (e.g., TPB, HBM, transtheoretical model) and see how, alone or in combination, 
these models better predict HPV vaccination.  
 Some have argued that the TPB assumes that the individual is an informed agent of their 
own behavior change. Other TPB examples may highlight weight loss or beginning an exercise 
regimen as a health behavior to measure, however those health behaviors are commonly taken up 
across genders, and one could assume that participants would know that exercise or weight loss 
might benefit them regardless of their individual gender. In the instance of HPV, men may not be 
acting as informed agents, and therefore only behavioral beliefs remained as a predictor of HPV 
vaccination intentions in my sample. In other words, if men do not see themselves at risk for 
HPV, then the TPB model may provide an adequate model of predicting behavioral intentions. 
This highlights the importance of behavioral beliefs in predicting male HPV vaccination 
intentions, and provides important information to physicians and interventionists attempting to 
increase HPV vaccination among males, by emphasizing the health benefits of HPV vaccination.  
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